Subject: Fwd: FW: Survey assessing the implementation barriers for some new drugs for treatment of multidrug-resistant TB (MDR-TB)
From: "Tea Jikia" <[email-masked]>
To: Mariana Mkurnali
Date: Mon, 10 Jul 2017 13:56:49 +0400

-----Original Message-----

From: POLISHCHUK, Olexandr <[email-masked]>

To: Tea Jikia ([email-masked]) <[email-masked]>, Tea Jikia
<[email-masked]>

Date: Sun, 9 Jul 2017 07:53:27 +0000

Subject: FW: Survey assessing the implementation barriers for some new drugs
for treatment of multidrug-resistant TB (MDR-TB)

Dear Tea,

Hope you are beck well.

Please find attached all
papers with regards to the survey.

They were sent according to
the WHO protocol and a delay may occur due to administrative reasons.

Please help to fill the
questionnaire in and send it to us with the survey information approval
letter.

Thank you in advance.

With best regards

Olexandr

From:
BOYAKHCHYAN, Varduhi On Behalf Of KLUGE, Hans Henri P.

Sent: 29 June 2017 15:06
To: [email-masked]';
[email-masked]
Cc: [email-masked]';
[email-masked]'; [email-masked]';
[email-masked]'; [email-masked]'; IVANUSA, Marijan; IVANUSA,
Marijan
Subject: Survey assessing the implementation barriers for
some new drugs for treatment of multidrug-resistant TB (MDR-TB)

Dear Colleagues,

This is to inform you that the World Health
Organization Global TB Programme, in collaboration with the World Health
Organization Regional Office for Europe, conduct a survey assessing the
implementation barriers for some new drugs for treatment of
multidrug-resistant TB (MDR-TB), namely bedaquiline (bdq) and delamanid
(dlm). The survey focuses on medicines regulatory issues for the
registration of these two products.

Invitation to participate in the survey, scope and
purposes, survey questionnaire and survey information approval are attached
herewith.

The survey questionnaire in English version is 4,5
pages only and is reasonably easy to be filled in.

We would highly appreciate your support to our project
and we kindly ask to send the filled in questionnaire and survey information
approval signed by the Ministry before the 15 July 2017 as explained in the
invitation letter.

Yours sincerely,

Dr Hans Kluge

Director, Division of Health Systems and Public
Health